Sara Mangsbo
Overview
Explore the profile of Sara Mangsbo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
422
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wilske F, Eriksson O, Amini R, Estrada S, Janols H, Khalil A, et al.
Intensive Care Med Exp
. 2025 Feb;
13(1):14.
PMID: 39904820
Background: Neutrophil granulocytes are important parts of the defence against bacterial infections. Their action is a two-edged sword, the mediators killing the intruding bacteria are at the same time causing...
2.
Mebrahtu A, Lauren I, Veerman R, Akpinar G, Lord M, Kostakis A, et al.
Nat Commun
. 2024 Nov;
15(1):9542.
PMID: 39500897
Current antibody-based immunotherapy depends on tumor antigen shedding for proper T cell priming. Here we select a novel human CD40 agonistic drug candidate and generate a bispecific antibody, herein named...
3.
Nazir F, Wiberg A, Muller M, Mangsbo S, Burman J
Brain Commun
. 2023 Jun;
5(3):fcad164.
PMID: 37274830
Multiple sclerosis is a highly complex and heterogeneous disease. At the onset it often presents as a clinically isolated syndrome. Thereafter relapses are followed by periods of remissions, but eventually,...
4.
Marking U, Havervall S, Greilert Norin N, Bladh O, Christ W, Gordon M, et al.
Nat Commun
. 2023 Mar;
14(1):1577.
PMID: 36949041
Vaccination offers protection against severe COVID-19 caused by SARS-CoV-2 omicron but is less effective against infection. Characteristics such as serum antibody titer correlation to protection, viral abundance and clearance of...
5.
Blom K, Marking U, Havervall S, Greilert Norin N, Gordon M, Garcia M, et al.
Lancet Infect Dis
. 2022 Jun;
22(7):943-945.
PMID: 35691303
No abstract available.
6.
Tolf A, Wiberg A, Muller M, Nazir F, Pavlovic I, Lauren I, et al.
JAMA Netw Open
. 2022 May;
5(5):e2211497.
PMID: 35544139
Importance: B-cell-depleting monoclonal antibodies are widely used for treatment of multiple sclerosis but are associated with an impaired response to vaccines. Objective: To identify factors associated with a favorable vaccine...
7.
Havervall S, Marking U, Greilert-Norin N, Gordon M, Ng H, Christ W, et al.
Clin Transl Immunology
. 2022 Apr;
11(4):e1388.
PMID: 35444806
Objective: To determine the long-term impact of prior SARS-CoV-2 infection on immune responses after COVID-19 vaccination. Methods: Using longitudinally collected blood samples from the COMMUNITY study, we determined binding (WHO...
8.
Lauren I, Havervall S, Ng H, Lord M, Pettke A, Greilert-Norin N, et al.
Immun Inflamm Dis
. 2022 Mar;
10(4):e595.
PMID: 35349756
Background: Cellular immune memory responses post coronavirus disease 2019 (COVID-19) have been difficult to assess due to the risks of contaminating the immune response readout with memory responses stemming from...
9.
Marking U, Havervall S, Greilert-Norin N, Ng H, Blom K, Nilsson P, et al.
Vaccines (Basel)
. 2022 Mar;
10(3).
PMID: 35334989
Heterologous primary immunization against SARS-CoV-2 is part of applied recommendations. However, little is known about duration of immune responses after heterologous vaccine regimens. To evaluate duration of immune responses after...
10.
Havervall S, Falk A, Klingstrom J, Ng H, Greilert-Norin N, Gabrielsson L, et al.
PLoS One
. 2022 Jan;
17(1):e0262169.
PMID: 35020778
Current SARS-CoV-2 serological assays generate discrepant results, and the longitudinal characteristics of antibodies targeting various antigens after asymptomatic to mild COVID-19 are yet to be established. This longitudinal cohort study...